EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials

Claire H Parker iD, Craig Slattery, Donal J Brennan iD, Carel W le Roux iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Claire H Parker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Pregnancy in Diabetics. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The prevalence of diabetes and obesity continues to rise in women of reproductive age, with significant implications for both mother and foetus. Glucagon‐like peptide‐1 receptor agonists are effective treatments of diabetes and obesity. However, no Glucagon‐like peptide‐1 receptor agonists are currently approved for use during pregnancy. We describe the outcomes of unplanned pregnancies during regulatory clinical trials of Glucagon‐like peptide‐1 receptor agonists submitted to the Food and Drug Administration and European Medicines Agency. Materials and Methods A search was conducted of the regulatory documentation published by the European Medicines Agency and the Food and Drug Administration on unplanned pregnancies during regulatory clinical trials of Glucagon‐like peptide‐1 receptor agonists. Clinical and Medical Reviews published by the Center for Drug Evaluation and Research at the Food and Drug Administration for every Glucagon‐like peptide‐1 receptor agonist prior to market authorisation were assessed to gather information on unplanned pregnancies that occurred while females were partaking in the clinical development programmes of such drugs.

Results

Evidence in women having planned pregnancies is lacking, and the only evidence thus far relies on pregnancies occurring inadvertently during Glucagon‐like peptide‐1 receptor agonist trials. The incidence of congenital abnormalities in humans appears relatively low following Glucagon‐like peptide‐1 receptor agonist use during pregnancy.

Conclusions

Key knowledge gaps must be addressed before the introduction of the Glucagon‐like peptide‐1 receptor agonist class of drugs for pregnant women. Currently, Glucagon‐like peptide‐1 receptor agonists should be stopped as soon as the patient becomes aware of a pregnancy. The establishment of patient registries designed to capture data relating to cases of Glucagon‐like peptide‐1 receptor agonist exposure during pregnancy is a high priority, and where data already exist, the findings need to be published.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsPregnancy in DiabeticsFemaleHumansPregnancyClinical Trials as TopicObesityPregnancy Outcome

Stichwörter der Autor:innen

GLP1‐RAGLP‐1GLP‐1 receptor agonistsfoetal outcomepregnancypregnancy risk

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, USA.
  • School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
  • University College Dublin School of Medicine, Catherine McCauley Research Centre, Mater Misericoridiae University Hospital, Dublin, Ireland.
  • Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.

ORCID-Profile: Claire H Parker, Donal J Brennan, Carel W le Roux

Zitieren

APA

Parker, C. H., Slattery, C., Brennan, D. J., & le Roux, C. W. (2025). Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16437

Vancouver

Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16437

BibTeX
@article{Parker2025,
  author = {Parker, Claire H and Slattery, Craig and Brennan, Donal J and le Roux, Carel W},
  title = {Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16437}
}
Kostenlos starten →